Literature DB >> 33603963

Potential of Cyclin-Dependent Kinase Inhibitors as Cancer Therapy.

Ahmed F Abdel-Magid1.   

Abstract

Entities:  

Year:  2021        PMID： 33603963      PMCID： PMC7883368          DOI： 10.1021/acsmedchemlett.1c00017

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.345


× No keyword cloud information.
  6 in total

Review 1.  Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015-2019).

Authors:  Concepción Sánchez-Martínez; María José Lallena; Sonia Gutiérrez Sanfeliciano; Alfonso de Dios
Journal:  Bioorg Med Chem Lett       Date:  2019-08-26       Impact factor: 2.823

2.  Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update.

Authors:  Solomon Tadesse; Elizabeth C Caldon; Wayne Tilley; Shudong Wang
Journal:  J Med Chem       Date:  2018-12-20       Impact factor: 7.446

Review 3.  Cyclin E1 and cyclin E2 in ER+ breast cancer: prospects as biomarkers and therapeutic targets.

Authors:  H H Milioli; S Alexandrou; E Lim; C E Caldon
Journal:  Endocr Relat Cancer       Date:  2020-05       Impact factor: 5.678

4.  Review of Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Hormone Receptor-Positive Advanced Breast Cancer.

Authors:  Keith A Hecht; Christopher Selby
Journal:  Ann Pharmacother       Date:  2018-08-06       Impact factor: 3.154

Review 5.  Small Molecule CDK Inhibitors for the Therapeutic Management of Cancer.

Authors:  Bharat Goel; Nancy Tripathi; Nivedita Bhardwaj; Shreyans K Jain
Journal:  Curr Top Med Chem       Date:  2020       Impact factor: 3.295

Review 6.  Cyclin-dependent kinases and rare developmental disorders.

Authors:  Pierre Colas
Journal:  Orphanet J Rare Dis       Date:  2020-08-06       Impact factor: 4.123
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.